Identification

Name
Perospirone
Accession Number
DB08922
Type
Small Molecule
Groups
Approved
Description

Perospirone is an atypical or second-generation antipsychotic of the azapirone family that antagonizes serotonin 5HT2A receptors and dopamine D2 receptors. It also displays affinity towards 5HT1A receptors as a partial agonist. It was introduced in Japan by Dainippon Sumitomo Pharma in 2001 for the treatment of acute and chronic schizophrenia and acute cases of bipolar mania. It is commonly present as the hydrated hydrochloride salt form. Classified as a neuroleptic agent, perospirone is shown to be effective against positive, negative and general symptoms in patients with schizophrenia [1]. It is also shown to be less associated with extrapyramidal symptoms as a side effect compared to Haloperidol.

Structure
Thumb
Synonyms
  • cis-N-(4-(4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl)butyl)-1,2-cyclohexanedicarboximide
  • SM-9018
International/Other Brands
Lullan (Dainippon Sumitomo Pharma)
Categories
UNII
N303OK87DT
CAS number
150915-41-6
Weight
Average: 426.58
Monoisotopic: 426.208947396
Chemical Formula
C23H30N4O2S
InChI Key
FBVFZWUMDDXLLG-HDICACEKSA-N
InChI
InChI=1S/C23H30N4O2S/c28-22-17-7-1-2-8-18(17)23(29)27(22)12-6-5-11-25-13-15-26(16-14-25)21-19-9-3-4-10-20(19)30-24-21/h3-4,9-10,17-18H,1-2,5-8,11-16H2/t17-,18+
IUPAC Name
(3aR,7aS)-2-{4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl}-octahydro-1H-isoindole-1,3-dione
SMILES
[H][[email protected]@]12CCCC[[email protected]]1([H])C(=O)N(CCCCN1CCN(CC1)C1=NSC3=CC=CC=C13)C2=O

Pharmacology

Indication

For the treatment of schizophrenia and acute cases of bipolar mania.

Structured Indications
Not Available
Pharmacodynamics

Perospirone is a serotonin 5-HT2 receptor inverse agonist and dopamine D2 receptor antagonist based on receptor binding experiments [3, 4] that binds to both receptors with high affinity. Perospirone is also a partial agonist at 5-HT1A receptors which are autoreceptors that stimulate the uptake of 5-HT and inhibit 5-HT release [7]. It also interacts with D4 receptors and α₁-adrenergic receptors as an antagonist, as well as histamine H1 receptor an inverse agonist. Binding to these receptors may explain sedative and hypotensive actions. Perospirone binds to D1 receptors with low affinity and minimal clinical significance [4].

Mechanism of action

Antagonism at D2 receptors is believed to relieve the positive symptoms of schizophrenia such as delusions, hallucinations, and thought disorders. Perospirone targets the mesolimbic patway to reverse the overactivity of the dopaminergic signalling via D2 receptors [7]. 5-HT2A antagonism is thought to allevaite the negative symptoms and cognitive impairments of schizophrenia. These receptors are Gi/Go coupled receptors that lead to decreased neurotransmitter release and neuronal inhibition when activated, thus play a role in dopamine release regulation. Perospirone targets these receptors in the nigrostriatal pathway to reduce dopamine release and function. In contrast, 5-HT2A receptor antagonism may improve the negative symptoms by enhancing dopamine and glutamate release in the mesocortical pathway [7]. 5-HT1A receptor activation further inhibits the release of 5-HT into the synaptic cleft.

TargetActionsOrganism
A5-hydroxytryptamine receptor 2A
inverse agonist
Human
AD(2) dopamine receptor
antagonist
Human
A5-hydroxytryptamine receptor 1A
partial agonist
Human
UHistamine H1 receptor
inverse agonist
Human
UD(4) dopamine receptor
antagonist
Human
UAlpha-1 adrenergic receptors
antagonist
Human
Absorption

Perospirone is rapidly absorbed following oral administration with the time to reach peak plasma concentration of 0.8 to 1.5 hours. A single oral dose of 8mg perospirone results in peak plasma concentration of 5.7 ug/L [2]. Perospirone is not reported to be accumulated after repeated dosing.

Volume of distribution

The mean volume of distribution following oral administration of 32 mg/day of perospirone is 1733L, with values ranging from 356-5246 L. It is shown to cross the placenta and be secreted into milk in pregnant rats [1].

Protein binding

Plasma protein binding ratio is 92% with extensive binding to serum albumin and α1-acid glycoprotein [2].

Metabolism

Perospirone undergoes rapid and extensive first-pass metabolism in the liver; the metabolic pathways involve hydroxylation, N-dealkylation, and S-oxidation, which are catalyzed by CYP1A1, 2C8, 2D6, and 3A4. CYP3A4 is reported to have highest level of contribution in perospirone metabolism. Hydroxyperospirone is formed from hydroxylation of the the cyclohexane-1,2-dicarboximide moiety and retains pharmacological action by mediating antiserotonergic effects, although with lower affinity [1].

Route of elimination

Perospirone is mainly excreted via renal elimination. 0.4% of of total dose is excreted as unchanged drug following oral administration of 8mg perospirone [2].

Half life

The elimination half life is approximately 1.9 hours following oral ingestion of 8mg perospirone [2].

Clearance

Apparent clearance rate is approximately 425.5 ± 150.3 L/h in patients receiving a single oral dose of 8mg perospirone [6].

Toxicity

Frequently experienced adverse effects include extrapyramidal symptoms, insomnia, and drowsiness. More serious adverse effect include neuroleptic malignant syndrome [1]. Oral LD50 value in rats is 870 mg/kg [MSDS].

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
5-hydroxytryptamine receptor 1A---(C;C)CC Allele (homozygous)Effect Directly StudiedThe presence of this polymorphism in HTR1A may indicate a higher level of efficacy in improving negative symptoms of schizophrenia when treated with perospirone.Details

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetaminePerospirone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetaminePerospirone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetaminePerospirone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Perospirone.Experimental
AbirateroneThe serum concentration of Perospirone can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Perospirone.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Perospirone.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Perospirone.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Perospirone.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Perospirone is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Perospirone is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Perospirone.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Perospirone is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Perospirone.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Perospirone.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Perospirone is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Perospirone.Approved, Illicit, Investigational
AmantadineThe therapeutic efficacy of Amantadine can be decreased when used in combination with Perospirone.Approved
AmiodaroneThe metabolism of Perospirone can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Perospirone is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Perospirone is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Perospirone.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Perospirone is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Perospirone is combined with Amperozide.Experimental
AmphetaminePerospirone may decrease the stimulatory activities of Amphetamine.Approved, Illicit
ApomorphineThe therapeutic efficacy of Apomorphine can be decreased when used in combination with Perospirone.Approved, Investigational
AprepitantThe serum concentration of Perospirone can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Perospirone.Approved, Investigational
ArtemetherThe metabolism of Perospirone can be decreased when combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Perospirone is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Perospirone.Approved
AtazanavirThe metabolism of Perospirone can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Perospirone can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Perospirone is combined with Azaperone.Vet Approved
AzelastinePerospirone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Perospirone is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Perospirone.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Perospirone is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Perospirone.Approved
BenzphetaminePerospirone may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Perospirone.Approved
BetaxololThe metabolism of Perospirone can be decreased when combined with Betaxolol.Approved
BoceprevirThe metabolism of Perospirone can be decreased when combined with Boceprevir.Withdrawn
BortezomibThe metabolism of Perospirone can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Perospirone can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Perospirone is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Perospirone.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Perospirone.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Perospirone is combined with Bromisoval.Experimental
BromocriptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Perospirone.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Perospirone is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Perospirone is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Perospirone is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Perospirone.Approved, Investigational
BuprenorphinePerospirone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Perospirone can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Perospirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Perospirone.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Perospirone is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Perospirone is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Perospirone is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Perospirone.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Perospirone.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Perospirone.Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Perospirone.Investigational
CarbamazepineThe metabolism of Perospirone can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Perospirone is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Perospirone.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Perospirone is combined with Carisoprodol.Approved
CelecoxibThe metabolism of Perospirone can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Perospirone can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Perospirone is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Perospirone.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Perospirone.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Perospirone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Perospirone.Approved
ChloroquineThe metabolism of Perospirone can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Perospirone is combined with Chlorphenamine.Approved
ChlorphenterminePerospirone may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Perospirone.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Perospirone.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Perospirone is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Perospirone can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Perospirone can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Perospirone can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Perospirone.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Perospirone.Approved
ClarithromycinThe metabolism of Perospirone can be decreased when combined with Clarithromycin.Approved
ClemastineThe risk or severity of adverse effects can be increased when Perospirone is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Perospirone is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Perospirone is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Perospirone.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Perospirone is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Perospirone is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Perospirone is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Perospirone is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Perospirone.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Perospirone is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Perospirone can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Perospirone.Approved
CobicistatThe serum concentration of Perospirone can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Perospirone can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Perospirone.Approved, Illicit
ConivaptanThe serum concentration of Perospirone can be increased when it is combined with Conivaptan.Approved, Investigational
CrisaboroleThe metabolism of Perospirone can be decreased when combined with Crisaborole.Approved
CrizotinibThe metabolism of Perospirone can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Perospirone is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Perospirone.Approved
CyclosporineThe metabolism of Perospirone can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Perospirone is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Perospirone can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Perospirone is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Perospirone.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Perospirone is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Perospirone can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Perospirone can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Perospirone can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Perospirone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Perospirone can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Perospirone.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Perospirone.Approved
DesipramineThe risk or severity of adverse effects can be increased when Perospirone is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Perospirone is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Perospirone.Approved
DetomidineThe risk or severity of adverse effects can be increased when Perospirone is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Perospirone is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Perospirone.Approved, Vet Approved
DextroamphetaminePerospirone may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Perospirone.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Perospirone.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Perospirone.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Perospirone.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Perospirone.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Perospirone is combined with Diethyl ether.Experimental
DiethylpropionPerospirone may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Perospirone is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Perospirone.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Perospirone.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Perospirone.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Perospirone.Experimental, Illicit
DiltiazemThe metabolism of Perospirone can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Perospirone is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Perospirone.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Perospirone.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Perospirone is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Perospirone is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Perospirone can be decreased when combined with Dosulepin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Perospirone is combined with Doxepin.Approved
DoxycyclineThe metabolism of Perospirone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Perospirone.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Perospirone.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Perospirone.Approved, Illicit
DronedaroneThe metabolism of Perospirone can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Perospirone.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Perospirone.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Perospirone.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Perospirone.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Perospirone.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Perospirone is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Perospirone is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Perospirone.Approved, Investigational
EliglustatThe metabolism of Perospirone can be decreased when combined with Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Perospirone is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Perospirone.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Perospirone is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Perospirone can be decreased when it is combined with Enzalutamide.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Perospirone.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Perospirone.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Perospirone.Approved
ErythromycinThe metabolism of Perospirone can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Perospirone.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Perospirone.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Perospirone.Approved
EthanolPerospirone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Perospirone.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Perospirone is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Perospirone is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Perospirone.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Perospirone is combined with Ethyl chloride.Experimental
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Perospirone.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Perospirone.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Perospirone is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Perospirone is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Perospirone is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Perospirone.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Perospirone is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Perospirone.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Perospirone is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Perospirone is combined with Felbamate.Approved
FelodipineThe metabolism of Perospirone can be decreased when combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Perospirone.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Perospirone.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Perospirone is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Perospirone is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Perospirone is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Perospirone can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Perospirone.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Perospirone is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Perospirone.Approved, Illicit
FluoxetineThe metabolism of Perospirone can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Perospirone.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Perospirone.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Perospirone.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Perospirone.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Perospirone is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Perospirone.Approved, Investigational
FosamprenavirThe metabolism of Perospirone can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Perospirone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Perospirone can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Perospirone.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Perospirone.Approved, Investigational
Fusidic AcidThe serum concentration of Perospirone can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Perospirone.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Perospirone is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Perospirone.Approved, Illicit
GepefrinePerospirone may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Perospirone.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Perospirone is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Perospirone.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Perospirone.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Perospirone.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Perospirone.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Perospirone.Approved
HydrocodonePerospirone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Perospirone.Approved, Illicit
HydroxyamphetaminePerospirone may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Perospirone.Approved
IdelalisibThe serum concentration of Perospirone can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Perospirone is combined with Iloperidone.Approved
ImatinibThe metabolism of Perospirone can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Perospirone is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Perospirone is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Perospirone can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Perospirone is combined with Indiplon.Investigational
Iofetamine I-123Perospirone may decrease the stimulatory activities of Iofetamine I-123.Approved
IrbesartanThe metabolism of Perospirone can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Perospirone can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Perospirone.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Perospirone.Approved, Vet Approved
IsoniazidThe metabolism of Perospirone can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Perospirone can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Perospirone can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Perospirone can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Perospirone.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Perospirone.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Perospirone.Approved
KetoconazoleThe metabolism of Perospirone can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Perospirone is combined with Lamotrigine.Approved, Investigational
LapatinibThe metabolism of Perospirone can be decreased when combined with Lapatinib.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Perospirone is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Perospirone.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Perospirone is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Perospirone is combined with Levocetirizine.Approved
LevodopaThe therapeutic efficacy of Levodopa can be decreased when used in combination with Perospirone.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Perospirone.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Perospirone.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Perospirone.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Perospirone.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Perospirone.Approved, Investigational
LisdexamfetaminePerospirone may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Perospirone.Approved
LofentanilThe risk or severity of adverse effects can be increased when Perospirone is combined with Lofentanil.Illicit
LopinavirThe metabolism of Perospirone can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Perospirone is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Perospirone is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Perospirone.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Perospirone.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Perospirone is combined with Lormetazepam.Approved
LosartanThe metabolism of Perospirone can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Perospirone can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Perospirone.Approved
LuliconazoleThe serum concentration of Perospirone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Perospirone can be increased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Perospirone can be decreased when combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Perospirone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Perospirone.Approved, Vet Approved
ManidipineThe metabolism of Perospirone can be decreased when combined with Manidipine.Approved
MaprotilineThe risk or severity of adverse effects can be increased when Perospirone is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Perospirone is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Perospirone is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Perospirone is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Perospirone is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Perospirone.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Perospirone is combined with Melperone.Approved
MephedronePerospirone may decrease the stimulatory activities of Mephedrone.Investigational
MephenterminePerospirone may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Perospirone.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Perospirone.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Perospirone is combined with Meptazinol.Experimental
MequitazinePerospirone may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Perospirone.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Perospirone is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Perospirone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Perospirone.Approved, Illicit
MethamphetaminePerospirone may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Perospirone.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Perospirone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Perospirone is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Perospirone.Approved
MethotrimeprazinePerospirone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Perospirone.Approved, Vet Approved
MethoxyphenaminePerospirone may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Perospirone is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Perospirone.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Perospirone is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Perospirone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Perospirone.Approved, Investigational
MetoprololThe metabolism of Perospirone can be decreased when combined with Metoprolol.Approved, Investigational
MetyrosinePerospirone may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Perospirone.Approved, Illicit
MidomafetaminePerospirone may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
MidostaurinThe metabolism of Perospirone can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Perospirone can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Perospirone.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Perospirone.Approved, Investigational
MirabegronThe metabolism of Perospirone can be decreased when combined with Mirabegron.Approved
MirtazapinePerospirone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Perospirone can be decreased when it is combined with Mitotane.Approved
MMDAPerospirone may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Perospirone.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Perospirone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Perospirone.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Perospirone.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Perospirone.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Perospirone.Approved, Investigational
NefazodoneThe metabolism of Perospirone can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Perospirone can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Perospirone can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Perospirone can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Perospirone can be decreased when combined with Nicardipine.Approved
NilotinibThe metabolism of Perospirone can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Perospirone.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Perospirone.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Perospirone is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Perospirone is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Perospirone is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Perospirone.Approved, Investigational
OlaparibThe metabolism of Perospirone can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Perospirone is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Perospirone.Approved
OpiumThe risk or severity of adverse effects can be increased when Perospirone is combined with Opium.Approved, Illicit
OrphenadrinePerospirone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Perospirone.Investigational
OsimertinibThe serum concentration of Perospirone can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Perospirone.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Perospirone is combined with Oxethazaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Perospirone.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Perospirone.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Perospirone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Perospirone.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Perospirone can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Perospirone.Approved
PanobinostatThe serum concentration of Perospirone can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydePerospirone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe metabolism of Perospirone can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Perospirone can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Perospirone is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Perospirone.Approved, Vet Approved
PentobarbitalThe metabolism of Perospirone can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Perospirone.Approved
PerazineThe risk or severity of adverse effects can be increased when Perospirone is combined with Perazine.Investigational
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Perospirone.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Perospirone.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Perospirone is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Perospirone.Approved
PhenibutThe risk or severity of adverse effects can be increased when Perospirone is combined with Phenibut.Experimental
PhenobarbitalThe metabolism of Perospirone can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Perospirone is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Perospirone is combined with Phenoxyethanol.Approved
PhenterminePerospirone may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe metabolism of Perospirone can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Perospirone.Approved
PioglitazoneThe metabolism of Perospirone can be decreased when combined with Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Perospirone is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Perospirone is combined with Pipotiazine.Approved
PiribedilThe therapeutic efficacy of Piribedil can be decreased when used in combination with Perospirone.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Perospirone is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Perospirone is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Perospirone is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Perospirone can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexolePerospirone may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Perospirone is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Perospirone.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Perospirone.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Perospirone.Approved
PrimidoneThe metabolism of Perospirone can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Perospirone.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Perospirone.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Perospirone.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Perospirone.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Perospirone is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Perospirone is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Perospirone.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Perospirone.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Perospirone is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Perospirone is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Perospirone is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Perospirone.Investigational
PseudoephedrinePerospirone may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Perospirone.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Perospirone.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Perospirone.Approved
QuinidineThe metabolism of Perospirone can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Perospirone can be decreased when combined with Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Perospirone is combined with Quinisocaine.Experimental
RabeprazoleThe metabolism of Perospirone can be decreased when combined with Rabeprazole.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Perospirone is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Perospirone is combined with Ramelteon.Approved, Investigational
RanolazineThe metabolism of Perospirone can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Perospirone.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Perospirone.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Perospirone.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Perospirone.Approved
RifabutinThe metabolism of Perospirone can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Perospirone can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Perospirone can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Perospirone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Perospirone is combined with Ritanserin.Investigational
RitobegronPerospirone may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirThe metabolism of Perospirone can be decreased when combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Perospirone.Approved
RolapitantThe metabolism of Perospirone can be decreased when combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Perospirone is combined with Romifidine.Vet Approved
RopinirolePerospirone may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Perospirone.Approved
RosiglitazoneThe metabolism of Perospirone can be decreased when combined with Rosiglitazone.Approved, Investigational
RotigotinePerospirone may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Perospirone.Approved
SaquinavirThe metabolism of Perospirone can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Perospirone is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Perospirone can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Perospirone.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Perospirone is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Perospirone.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Perospirone.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Perospirone.Approved, Vet Approved
SildenafilThe metabolism of Perospirone can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Perospirone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Perospirone can be increased when it is combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Perospirone.Approved
St. John's WortThe serum concentration of Perospirone can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Perospirone can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Perospirone.Approved, Investigational
SulfamethoxazoleThe metabolism of Perospirone can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Perospirone can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Perospirone is combined with Sulpiride.Approved
SultoprideThe risk or severity of adverse effects can be increased when Perospirone is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Perospirone.Approved, Investigational
SuvorexantPerospirone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TamoxifenThe metabolism of Perospirone can be decreased when combined with Tamoxifen.Approved
TandospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Perospirone.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Perospirone is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Perospirone.Approved
TelaprevirThe metabolism of Perospirone can be decreased when combined with Telaprevir.Withdrawn
TelithromycinThe metabolism of Perospirone can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Perospirone.Approved
TerbinafineThe metabolism of Perospirone can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TeriflunomideThe metabolism of Perospirone can be decreased when combined with Teriflunomide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Perospirone.Approved
TetracaineThe risk or severity of adverse effects can be increased when Perospirone is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Perospirone is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Perospirone.Investigational
ThalidomidePerospirone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Perospirone.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Perospirone.Approved, Vet Approved
ThioridazineThe metabolism of Perospirone can be decreased when combined with Thioridazine.Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Perospirone.Approved
TiagabineThe risk or severity of adverse effects can be increased when Perospirone is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Perospirone is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Perospirone can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Perospirone is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Perospirone is combined with Tilidine.Experimental
TipranavirThe metabolism of Perospirone can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Perospirone is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Perospirone can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Perospirone is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Perospirone is combined with Topiramate.Approved
TopiroxostatThe metabolism of Perospirone can be decreased when combined with Topiroxostat.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Perospirone.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Perospirone.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Perospirone.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Perospirone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Perospirone.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Perospirone is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Perospirone is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Perospirone.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Perospirone is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Perospirone.Approved, Vet Approved
TrimethoprimThe metabolism of Perospirone can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Perospirone is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Perospirone is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Perospirone.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Perospirone.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Perospirone is combined with Veralipride.Experimental
VerapamilThe metabolism of Perospirone can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Perospirone is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Perospirone.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Perospirone is combined with Vinyl ether.Experimental
VoriconazoleThe metabolism of Perospirone can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Perospirone is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Perospirone is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Perospirone is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Perospirone.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Perospirone is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Perospirone is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Perospirone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Perospirone is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Perospirone.Approved, Investigational
ZolpidemPerospirone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Perospirone is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Perospirone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Perospirone is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Perospirone.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Yasui-Furukori N, Furukori H, Nakagami T, Saito M, Inoue Y, Kaneko S, Tateishi T: Steady-state pharmacokinetics of a new antipsychotic agent perospirone and its active metabolite, and its relationship with prolactin response. Ther Drug Monit. 2004 Aug;26(4):361-5. [PubMed:15257064]
  2. Onrust SV, McClellan K: Perospirone. CNS Drugs. 2001;15(4):329-37; discussion 338. [PubMed:11463136]
  3. Hirose A, Kato T, Ohno Y, Shimizu H, Tanaka H, Nakamura M, Katsube J: Pharmacological actions of SM-9018, a new neuroleptic drug with both potent 5-hydroxytryptamine2 and dopamine2 antagonistic actions. Jpn J Pharmacol. 1990 Jul;53(3):321-9. [PubMed:1975278]
  4. Kishi T, Iwata N: Efficacy and tolerability of perospirone in schizophrenia: a systematic review and meta-analysis of randomized controlled trials. CNS Drugs. 2013 Sep;27(9):731-41. doi: 10.1007/s40263-013-0085-7. [PubMed:23812802]
  5. Takeuchi T, Furuta K, Hirasawa T, Masaki H, Yukizane T, Atsuta H, Nishikawa T: Perospirone in the treatment of patients with delirium. Psychiatry Clin Neurosci. 2007 Feb;61(1):67-70. [PubMed:17239041]
  6. Zou JJ, Liu L, Di B, Ding L, Zhu YB, Fan HW, Xiao DW, Wang GJ: Estimation of Perospirone in Human Plasma by LC–MS–MS and Its Application to Pharmacokinetics Study Chromatographia. 2008 August 1;68(3-4):239–243.
  7. 45. (2012). In Rang and Dale's Pharmacology (7th ed., pp. 553-563). Edinburgh: Elsevier/Churchill Livingstone. [ISBN:978-0-7020-3471-8]
External Links
ChemSpider
103202
ChEBI
94777
ChEMBL
CHEMBL1472975
MSDS
Download (1.62 MB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)95-97 as hydrochloride formMSDS
Predicted Properties
PropertyValueSource
Water Solubility0.0317 mg/mLALOGPS
logP3.94ALOGPS
logP3.74ChemAxon
logS-4.1ALOGPS
pKa (Strongest Basic)7.73ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area56.75 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity120.29 m3·mol-1ChemAxon
Polarizability48.39 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-004i-0420900000-590f813b91a94ad578ab

Taxonomy

Description
This compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
N-arylpiperazines
Alternative Parents
Isoindolones / Benzothiazoles / Isoindoles / Dialkylarylamines / N-alkylpiperazines / Aminothiazoles / Benzenoids / Pyrrolidine-2-ones / Imidolactams / N-substituted carboxylic acid imides
show 11 more
Substituents
N-arylpiperazine / Isoindolone / 1,2-benzothiazole / Isoindoline / Isoindole / Isoindole or derivatives / Dialkylarylamine / N-alkylpiperazine / 1,2-thiazolamine / Carboxylic acid imide, n-substituted
show 27 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inverse agonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Tanaka H, Ohno Y, Nakamura M: Localization and pharmacological characterization of [3H]perospirone-binding sites in rat brain. Gen Pharmacol. 1998 Jul;31(1):159-64. [PubMed:9595296]
  2. Kishi T, Iwata N: Efficacy and tolerability of perospirone in schizophrenia: a systematic review and meta-analysis of randomized controlled trials. CNS Drugs. 2013 Sep;27(9):731-41. doi: 10.1007/s40263-013-0085-7. [PubMed:23812802]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Tanaka H, Ohno Y, Nakamura M: Localization and pharmacological characterization of [3H]perospirone-binding sites in rat brain. Gen Pharmacol. 1998 Jul;31(1):159-64. [PubMed:9595296]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Partial agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Shiwa T, Amano T, Matsubayashi H, Seki T, Sasa M, Sakai N: Perospirone, a novel antipsychotic agent, hyperpolarizes rat dorsal raphe neurons via 5-HT1A receptor. J Pharmacol Sci. 2003 Sep;93(1):114-7. [PubMed:14501160]
  2. Tanaka H, Ohno Y, Nakamura M: Localization and pharmacological characterization of [3H]perospirone-binding sites in rat brain. Gen Pharmacol. 1998 Jul;31(1):159-64. [PubMed:9595296]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inverse agonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Kishi T, Iwata N: Efficacy and tolerability of perospirone in schizophrenia: a systematic review and meta-analysis of randomized controlled trials. CNS Drugs. 2013 Sep;27(9):731-41. doi: 10.1007/s40263-013-0085-7. [PubMed:23812802]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Sh3 domain binding
Specific Function
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins ...
Gene Name
DRD4
Uniprot ID
P21917
Uniprot Name
D(4) dopamine receptor
Molecular Weight
48359.86 Da
References
  1. Kishi T, Iwata N: Efficacy and tolerability of perospirone in schizophrenia: a systematic review and meta-analysis of randomized controlled trials. CNS Drugs. 2013 Sep;27(9):731-41. doi: 10.1007/s40263-013-0085-7. [PubMed:23812802]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...

Components:
References
  1. Kishi T, Iwata N: Efficacy and tolerability of perospirone in schizophrenia: a systematic review and meta-analysis of randomized controlled trials. CNS Drugs. 2013 Sep;27(9):731-41. doi: 10.1007/s40263-013-0085-7. [PubMed:23812802]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Yasui-Furukori N, Furukori H, Nakagami T, Saito M, Inoue Y, Kaneko S, Tateishi T: Steady-state pharmacokinetics of a new antipsychotic agent perospirone and its active metabolite, and its relationship with prolactin response. Ther Drug Monit. 2004 Aug;26(4):361-5. [PubMed:15257064]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Yasui-Furukori N, Furukori H, Nakagami T, Saito M, Inoue Y, Kaneko S, Tateishi T: Steady-state pharmacokinetics of a new antipsychotic agent perospirone and its active metabolite, and its relationship with prolactin response. Ther Drug Monit. 2004 Aug;26(4):361-5. [PubMed:15257064]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Yasui-Furukori N, Furukori H, Nakagami T, Saito M, Inoue Y, Kaneko S, Tateishi T: Steady-state pharmacokinetics of a new antipsychotic agent perospirone and its active metabolite, and its relationship with prolactin response. Ther Drug Monit. 2004 Aug;26(4):361-5. [PubMed:15257064]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Yasui-Furukori N, Furukori H, Nakagami T, Saito M, Inoue Y, Kaneko S, Tateishi T: Steady-state pharmacokinetics of a new antipsychotic agent perospirone and its active metabolite, and its relationship with prolactin response. Ther Drug Monit. 2004 Aug;26(4):361-5. [PubMed:15257064]

Drug created on September 21, 2013 15:35 / Updated on October 02, 2017 06:11